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http://dx.doi.org/10.1016/j.jmii.2013Necrotizing fasciitis caused by Vibrio vulnificus is rarely reported in children. We describe a 12-
year-old immunocompetent boy with necrotizing fasciitis caused by V. vulnificus. He was cured
by radical and serial debridement and salvage therapy with intravenous cefpirome plus tigecy-
cline. The in vitro antibacterial activity of combination regimens and a literature review of pe-
diatric V. vulnificus infection are described.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction marine and estuarine sea life along the coast of Taiwan.Vibrio vulnificus is a halophilic, bacillary, Gram-negative
bacterium that is endemic and increasingly prevalent in
warm estuarine and marine environments throughout the
world. The bacterium has a commensal relationship withof Medicine, Chi Mei Medical
ng City, Tainan 710, Taiwan.
om (H.-J. Tang).
to this paper.
an Society of Microbiology. Publis
commons.org/licenses/by-nc-nd/
.04.008Necrotizing fasciitis caused by V. vulnificus is rarely re-
ported in children. Traditional therapy with a third-
generation cephalosporin combined with minocycline is
usually synergistic and effective. We report the case of a
12-year-old boy with rapidly progressive necrotizing fascii-
tis caused by V. vulnificus who exhibited a poor response to
ceftazidime plus minocycline. However, salvage therapy
with cefpirome plus tigecycline can stabilize wound con-
ditions. In vitro antimicrobial susceptibility and a time-
killing study of combination therapy were assessed andhed by Elsevier Taiwan LLC. This is an open access article under the
4.0/).
Figure 1. Summary of the clinical course in our patient.
Tigecyline treatment of Vibrio vulnificus in a child 139carried out a literature review of pediatric V. vulnificus
infection.Case report
A 12-year-old boy without underlying disease was injured
by wooden stick penetration of his left leg. The same af-
ternoon, he handled shrimps at the fish market. Painful
swelling of his left leg developed by midnight, and he was
sent to the emergency department for evaluation.
On physical examination, he looked ill and was febrile,
with a body temperature of 39.6C, pulse rate of 79 beats/
min, respiratory rate of 22 breaths/min, and blood pressure
of 110/58 mmHg. His left lower leg was mildly tender and
swollen with no obvious open wounds. Initial laboratory
studies showed a hemoglobin level of 11.6 g/dL, hematocrit
of 44.5%, white blood cell (WBC) count of 11,600/mm3
(neutrophils 90.7%, band form WBCs 0%, and lymphocytes
5.5%), platelet count of 262,000/mm3, and serum C-reac-
tive protein of 0.9 mg/dL (normal range < 6 mg/dL). Blood
culture results were negative. An emergency consultation
with a plastic surgeon was arranged because of progression
of swelling and pain. The leg was very tender and a duskyFigure 2. Time-killing curves for 2  105 CFU/ml Vibrio vulnificu
tigecycline alone for 48 hours and (B) 1/2 MIC of ceftazidime and/discoloration was noted on the upper lateral part of the leg.
In addition, the patient was in shock. An emergency fas-
ciotomy was performed and intravenous ceftazidime (1 g
every 8 hours) with minocycline (80 mg every 12 hours) was
immediately administered. On Day 4 following admission,
the dusty discoloration extended to the left knee, with
hemorrhagic bullae developing circumferentially in the left
leg and dorsal foot. We performed radical debridement of
all the necrotic skin and subcutaneous tissue because of the
uncontrolled infection. A wound culture revealed V. vulni-
ficus. The patient’s condition deteriorated further, with
erythema extending to the left thigh and inguinal area on
Day 6. Therefore, we escalated the antibiotic therapy to
cefpirome (2 g every 12 hours) and tigecycline (40 mg every
12 hours) and performed another fasciotomy in the
erythematous areas in the inguinal region.
The infection gradually abated. Because of the partial
loss of gastrocnemius muscle with exposure of the Achilles
tendon, we performed a mesh split-thickness skin graft
(with 1:3 expansions) following right latissimus dorsal free
flap coverage of the Achilles tendon. The patient was dis-
charged uneventfully on Day 47 and was monitored in the
outpatient clinic. Fig. 1 summarizes the clinical course of
this disease.s (Vv 14-2) co-cultivated with (A) 1/2 MIC of cefpirome or/and
or minocycline for 48 hours.
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In vitro susceptibility studies
Initially, we suspected high minimal inhibitory concentra-
tions (MICs) of ceftazidime and minocycline for the isolate.
However, we checked the MICs for ceftazidime, minocy-
cline, cefpirome, and tigecycline by the agar dilution
method and found low MIC values for all four antimicrobial
agents (minocycline 0.125 mg/mL, tigecycline 0.125 mg/mL,
cefpirome 0.25 mg/mL, and ceftazidime 0.25 mg/mL).
Moreover, MICs measured by the macrodilution method
with a high inoculum of 1  107 CFU/mL, simulating severe
infection with a high bacterial load, were similar for min-
ocycline (0.5 mg/mL) and tigecycline (0.5 mg/mL). However,
the MICs for ceftazidime and cefpirome at a high inoculum
were 16- and 32-fold higher, respectively, than for a stan-
dard inoculum.
Time-killing studies were used to evaluate the antibac-
terial effect of two combination regimens (Fig. 2). At the
concentration of 1/2 MIC for each drug, compared to bac-
terial regrowth in the presence of cefpirome or ceftazidime
alone, tigecycline (Fig. 2A) or minocycline alone (Fig. 2B)
exerted rapid antibacterial activity against this V. vulnificus
isolate. For combination regimens, we can only conclude
that no antagonism occurred. Two factors may explain the
in vitro and in vivo treatment discrepancy. First, the con-
centration we used in the time-killing study was 1/2 MIC,
which is lower than serum levels achieved in humans.
Therefore, the in vivo effect seems to be better. Second,
tigecycline has an immunomodulation effect that may
explain the discrepancy.
Literature review
To date, only six children with necrotizing soft tissue in-
fections caused by V. vulnificus have been described (Table
1).1e5 Three children had an underlying illness, including
nephritic syndrome, thalassemia major, and congenital
spherocytosis,1,2 but three cases, including our patient, had
no underlying disease. Intriguingly, four children progressed
rapidly to septic shock, but only one expired; another pa-
tient underwent an above-the-knee amputation. Except for
one patient, all the others had exposure histories consisting
of consumption of undercooked seafood, seawater contact,
or direct invasion through a wound.
Traditionally, combination therapy with a third-
generation cephalosporin and tetracycline or its analogs
has an in vitro synergistic effect against V. vulnificus and is
more effective than single-agent therapy for serious in-
fections.6 With regard to the poor response to standard
minocycline and ceftazidime therapy in our patient, we
suppose that high soft-tissue concentrations and the cyto-
kine immunomodulation effect of tigecycline could be
important factors. However, further animal studies should
be performed to confirm this hypothesis. Tigecycline, a
member of a new antibiotic class of glycylcyclines, exhibits
good tissue penetration and potent antibacterial activity
against V. vulnificus.7 For skin and soft-tissue infections,
high tissue concentrations of tigecycline have been docu-
mented.8 However, clinical application of tigecycline for
Tigecyline treatment of Vibrio vulnificus in a child 141invasive Vibrio infections has not been reported before.
The clinical progression of necrotizing fasciitis in the pre-
sent case was halted by the combination regimen of cef-
pirome plus tigecycline. An in vitro time-killing study
demonstrated rapid antibacterial activity of tigecycline
against the causative isolate and no antagonism for the
combination of tigecycline and cefpirome.
It is well known that an excess of pro-inflammatory cy-
tokines induced by Gram-negative bacteria is associated
with the clinical manifestations of septic shock and
increased mortality.9 Tetracycline and its derivatives, such
as minocycline, a bacteriostatic antibiotic, have not only
antibacterial but also immunomodulatory effects.10 In a
murine in vivo model of V. vulnificus infection, peritoneal
fluid cytokine levels in the cefotaximeeminocycline com-
bination therapy group were significantly lower than in
groups treated with cefotaxime or minocycline alone.11 In
addition, tigecycline altered cytokine production and
reduced T-cell proliferation in vitro, suggesting an immu-
nomodulatory effect independent of its antimicrobial ef-
fect.12 Such immunomodulatory activity of tigecycline
could have contributed to the excellent therapeutic
response of our patient. Thus, tigecycline-based therapy,
alone or in combination, may be one option for treatment
of invasive V. vulnificus infections.
In conclusion, necrotizing soft tissue infections caused by
V. vulnificus are extremely rare in children, and immuno-
competent children may be affected. In addition to the
combination of a third-generation cephalosporin and tetra-
cycline or its analogs, tigecycline-based salvage therapymay
be consideredas an alternative choice for invasive infections.
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